Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1-32 (canceled).
- 33. (new) An isolated monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601.
 - 34. (new) A nucleic acid encoding the monoclonal antibody of claim 33.
- 35. (new) The monoclonal antibody of claim 33, wherein said monoclonal antibody specifically binds to amino acids 1-42 of the polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601.
- 36. (new) A pharmaceutical composition comprising a monoclonal antibody according to claim 33 and a pharmaceutically acceptable carrier.
- 37. (new) The monoclonal antibody of claim 33, wherein said antibody is a chimeric antibody.
- 38. (new) The monoclonal antibody of claim 33, wherein said antibody is a Fab fragment.
- 39. (new) The monoclonal antibody of claim 33, wherein said antibody is a Fv fragment.
- 40. (new) The monoclonal antibody of claim 33, wherein said antibody is a scFv.

41. (new) The monoclonal antibody of claim 33 further comprising a reporter group.

- 42. (new) The monoclonal antibody of claim 33 further comprising a therapeutic moiety.
- 43. (new) The monoclonal antibody of claim 42, wherein the therapeutic moiety is a radionuclide.
- 44. (new) A pharmaceutical composition comprising a monoclonal antibody of claim 43, and a pharmaceutically acceptable carrier.
- 45. (new) A method for the treatment of a hematological malignancy in a mammalian subject, the method comprising:

administering to the subject an effective amount of a pharmceutical composition comprising an isolated monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601 and a pharmaceutically acceptable carrier.

- 46. (new) The method of claim 45, wherein the hematological malignancy is associated with overexpression of Ly1448.
- 47. (new) The method of claim 45, wherein the hematological malignancy is selected from the group consisting of lymphoma, B cell leukemia, multiple myeloma, and combinations thereof.
- 48. (new) The method of claim 45, wherein the mammalian subject is a human.
 - 49. (new) The method of claim 45, wherein the administration is intravenous.

- 50. (new) A method for the detection of a hematological malignancy in a patient, said method comprising:
- (a) contacting a biological sample from the patient with a monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601, whereby said monoclonal antibody forms a complex with a polypeptide encoded by SEQ ID NO:9601
 - (b) detecting the amount of said complex, thereby detecting cancer in said patient.
- 51. (new) The method of claim 50, wherein the hematological malignancy is selected from the group consisting of: lymphoma, B cell leukemia, and multiple myeloma, and combinations thereof.
- 52. (new) A kit for detecting a hematological malignancy cell, said kit comprising:

a monoclonal antibody that specifically binds to a polypeptide encoded by a nucleic acid sequence set forth in SEQ ID NO: 9601; and

instructions for use.